CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage.
Clonal dynamics in pediatric B-cell precursor acute lymphoblastic leukemia with very early relapse.
Nondisjunction of chromosomes leading to hyperdiploid childhood B-cell precursor acute lymphoblastic leukemia is an early event during leukemogenesis.
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.
Gupta S, Rau RE, Kairalla JA, Rabin KR, Wang C, Angiolillo AL, Alexander S, Carroll AJ, Conway S, Gore L, Kirsch I, Kubaney HR, Li AM, McNeer JL, Militano O, Miller TP, Moyer Y, O'Brien MM, Okada M, Reshmi SC, Shago M, Wagner E, Winick N, Wood BL, Haworth-Wright T, Zaman F, Zugmaier G, Zupanec S, Devidas M, Hunger SP, Teachey DT, Raetz EA, Loh ML.
N Engl J Med. 2025 Feb 27;392(9):875-891. doi: 10.1056/NEJMoa2411680. Epub 2024 Dec 7.
International Consensus Classification of acute lymphoblastic leukemia/lymphoma.
Duffield AS, Mullighan CG, Borowitz MJ.
Virchows Arch. 2023 Jan;482(1):11-26. doi: 10.1007/s00428-022-03448-8. Epub 2022 Nov 24.
Emerging molecular subtypes and therapies in acute lymphoblastic leukemia.
Davis K, Sheikh T, Aggarwal N.
Semin Diagn Pathol. 2023 May;40(3):202-215. doi: 10.1053/j.semdp.2023.04.003. Epub 2023 Apr 9.
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.
Jabbour E, Short NJ, Jain N, Haddad FG, Welch MA, Ravandi F, Kantarjian H.
J Hematol Oncol. 2023 Mar 16;16(1):22. doi: 10.1186/s13045-023-01409-5.
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.
Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, Halton E, Wang X, Senechal B, Purdon T, Cross JR, Liu H, Vachha B, Chen X, DeAngelis LM, Li D, Bernal Y, Gonen M, Wendel HG, Sadelain M, Brentjens RJ.
Cancer Discov. 2018 Aug;8(8):958-971. doi: 10.1158/2159-8290.CD-17-1319. Epub 2018 Jun 7.
Ph-like acute lymphoblastic leukemia in adults: understanding pathogenesis, improving outcomes, and future directions for therapy.
Aldoss I, Gu Z, Afkhami M, Mokhtari S, Pullarkat V.
Leuk Lymphoma. 2023 Jun;64(6):1092-1101. doi: 10.1080/10428194.2023.2197538. Epub 2023 Apr 6.
Interleukin-7 receptor alpha mutational activation can initiate precursor B-cell acute lymphoblastic leukemia.
Almeida ARM, Neto JL, Cachucho A, Euzébio M, Meng X, Kim R, Fernandes MB, Raposo B, Oliveira ML, Ribeiro D, Fragoso R, Zenatti PP, Soares T, de Matos MR, Corrêa JR, Duque M, Roberts KG, Gu Z, Qu C, Pereira C, Pyne S, Pyne NJ, Barreto VM, Bernard-Pierrot I, Clappier E, Mullighan CG, Grosso AR, Yunes JA, Barata JT.
Nat Commun. 2021 Dec 14;12(1):7268. doi: 10.1038/s41467-021-27197-5.
Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features.
Iacobucci I, Zeng AGX, Gao Q, Garcia-Prat L, Baviskar P, Shah S, Murison A, Voisin V, Chan-Seng-Yue M, Cheng C, Qu C, Bailey C, Lear M, Witkowski MT, Zhou X, Zaldivar Peraza A, Gangwani K, Advani AS, Luger SM, Litzow MR, Rowe JM, Paietta EM, Stock W, Dick JE, Mullighan CG.
Nat Cancer. 2025 Jul;6(7):1242-1262. doi: 10.1038/s43018-025-00987-2. Epub 2025 Jun 27.
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce S, Garris R, Keating MJ, Cortes J, Kantarjian HM.
J Clin Oncol. 2010 Aug 20;28(24):3880-9. doi: 10.1200/JCO.2009.26.9456. Epub 2010 Jul 26.
Blinatumomab in Practice.
Lantz J, Pham N, Jones C, Reed D, El Chaer F, Keng M.
Curr Hematol Malig Rep. 2024 Feb;19(1):1-8. doi: 10.1007/s11899-023-00714-7. Epub 2023 Dec 7.
